

Press Release

Regulated information

EURONEXT INTRODUCES STOCK OPTIONS ON ARSEUS

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 16 December 2013 – Euronext N.V., a wholly owned subsidiary of IntercontinentalExchange Group, Inc. (NYSE: ICE), will introduce options on the shares of Arseus (option trading symbol: RCU). The options will be available as of 16 December 2013 on the derivatives market of Euronext Brussels.

Arseus is a multinational group of companies that provides products, services and concepts for professionals active in the healthcare sector in 30 countries in Europe, North America, South America, Asia and Australia. Arseus is active in the markets for pharmaceutical compounding for pharmacies, medical ICT solutions, and dental, medical and surgical products and concepts.

Ger van Jeveren, CEO van Arseus: *"The listing of Arseus on Euronext Brussels and Amsterdam on October 5, 2007 was an important milestone for Arseus. Both the company and the stock price have shown strong growth since the listing. Arseus has developed rapidly into a leading company with a strong focus on innovative products and concepts with substantial added value. The listing of options on the shares of our company marks a further step in Arseus' development. We believe that this may offer shareholders an alternative financial instrument on Euronext, enhance the liquidity of our share, and increase the visibility of Arseus in the financial markets."*

Vincent Van Dessel, CEO and Chairman of Euronext Brussels: *"We are pleased to announce the introduction of the Arseus options, providing investors with new investment opportunities. Arseus option class will benefit from the growing interest in Belgian options we've seen over the past year."*

Leen Van Wambeke, Senior Business Development Manager Benelux at Euronext Brussels added: *"The listing of this new option class brings the total number of listed Individual Equity Options in Brussels to 21. With the addition of the Arseus option class to our existing central order book contracts, we are offering our market participants a highly diversified set of liquid derivatives for their investment needs."*

¹ This press release was sent out by Arseus NV and Arseus BV.

These American-style options will expire on the third Friday of the contract month and will have initial maturities of 1, 2, 3, 6, 9 and 12 months. Each option will represent 100 shares in RCU and will be cleared via LCH.Clearnet SA.

Euronext lists over 200 equity options (also known as individual stock options) on leading European companies via the Amsterdam, Brussels, London and Paris central order books.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Arseus

Marieke Palstra : Tel. +31 (0)88 33 11 213

marieke.palstra@arseus.com

Euronext Brussels

Jean-Yves Daxhelet : Tel. +32 (0)2 213 13 03

jean-yves.daxhelet@interelgroup.com

About Arseus

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem (Belgium), and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam (the Netherlands).